Published in Transfus Med Hemother on May 16, 2008
Cryopreservation of Human Stem Cells for Clinical Application: A Review. Transfus Med Hemother (2011) 1.23
Platelet lysate as replacement for fetal bovine serum in mesenchymal stromal cell cultures. Transfus Med Hemother (2013) 1.08
Clinical Protocols for the Isolation and Expansion of Mesenchymal Stromal Cells. Transfus Med Hemother (2008) 1.07
Innate immune system and preeclampsia. Front Immunol (2014) 0.98
Management of fibrosis: the mesenchymal stromal cells breakthrough. Stem Cells Int (2014) 0.96
Mitigation of Lethal Radiation Syndrome in Mice by Intramuscular Injection of 3D Cultured Adherent Human Placental Stromal Cells. PLoS One (2013) 0.88
Improvement of contraction force in injured skeletal muscle after autologous mesenchymal stroma cell transplantation is accompanied by slow to fast fiber type shift. Transfus Med Hemother (2013) 0.84
Basic Biology of Mesenchymal Stem Cells. Transfus Med Hemother (2008) 0.77
Immunobiology of dendritic cells. Annu Rev Immunol (2000) 23.65
Mesenchymal stem cells within tumour stroma promote breast cancer metastasis. Nature (2007) 15.20
Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood (2004) 13.79
Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. Lancet (2004) 11.77
Self-renewing osteoprogenitors in bone marrow sinusoids can organize a hematopoietic microenvironment. Cell (2007) 10.13
Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli. Blood (2002) 9.40
Adult rat and human bone marrow stromal cells differentiate into neurons. J Neurosci Res (2000) 7.87
Bone-marrow haematopoietic-stem-cell niches. Nat Rev Immunol (2006) 7.20
Mesenchymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivo. Exp Hematol (2002) 6.92
Administered mesenchymal stem cells protect against ischemic acute renal failure through differentiation-independent mechanisms. Am J Physiol Renal Physiol (2005) 6.71
Isolated allogeneic bone marrow-derived mesenchymal cells engraft and stimulate growth in children with osteogenesis imperfecta: Implications for cell therapy of bone. Proc Natl Acad Sci U S A (2002) 6.05
Human bone marrow stromal cells inhibit allogeneic T-cell responses by indoleamine 2,3-dioxygenase-mediated tryptophan degradation. Blood (2004) 6.02
Mesenchymal stem cells enhance wound healing through differentiation and angiogenesis. Stem Cells (2007) 5.83
Mesenchymal stem cells ameliorate experimental autoimmune encephalomyelitis inducing T-cell anergy. Blood (2005) 5.82
Mesenchymal stem cells: potential precursors for tumor stroma and targeted-delivery vehicles for anticancer agents. J Natl Cancer Inst (2004) 5.39
HLA expression and immunologic properties of differentiated and undifferentiated mesenchymal stem cells. Exp Hematol (2003) 5.35
Inhibition of T cell proliferation by macrophage tryptophan catabolism. J Exp Med (1999) 5.26
Bone marrow mesenchymal stem cells inhibit the response of naive and memory antigen-specific T cells to their cognate peptide. Blood (2002) 5.14
Human mesenchymal stem cells modulate B-cell functions. Blood (2005) 5.12
Suppression of allogeneic T-cell proliferation by human marrow stromal cells: implications in transplantation. Transplantation (2003) 5.07
Mesenchymal stem cells inhibit and stimulate mixed lymphocyte cultures and mitogenic responses independently of the major histocompatibility complex. Scand J Immunol (2003) 4.62
Role for interferon-gamma in the immunomodulatory activity of human bone marrow mesenchymal stem cells. Stem Cells (2005) 4.26
Bone marrow-derived cells as progenitors of lung alveolar epithelium. Development (2001) 4.13
Human mesenchymal stem cells inhibit differentiation and function of monocyte-derived dendritic cells. Blood (2005) 4.10
Human mesenchymal stem cells alter antigen-presenting cell maturation and induce T-cell unresponsiveness. Blood (2004) 4.04
Bone marrow mesenchymal stem cells induce division arrest anergy of activated T cells. Blood (2004) 4.03
Clinical treatment of radiotherapy tissue damage by lipoaspirate transplant: a healing process mediated by adipose-derived adult stem cells. Plast Reconstr Surg (2007) 4.00
Human mesenchymal stem cells engraft and demonstrate site-specific differentiation after in utero transplantation in sheep. Nat Med (2000) 3.94
Rapid hematopoietic recovery after coinfusion of autologous-blood stem cells and culture-expanded marrow mesenchymal stem cells in advanced breast cancer patients receiving high-dose chemotherapy. J Clin Oncol (2000) 3.94
Nitric oxide plays a critical role in suppression of T-cell proliferation by mesenchymal stem cells. Blood (2006) 3.52
Human leukocyte antigen-G5 secretion by human mesenchymal stem cells is required to suppress T lymphocyte and natural killer function and to induce CD4+CD25highFOXP3+ regulatory T cells. Stem Cells (2007) 3.49
Sarcoma derived from cultured mesenchymal stem cells. Stem Cells (2006) 3.40
IL-6 switches the differentiation of monocytes from dendritic cells to macrophages. Nat Immunol (2000) 3.39
Mesenchymal stem cells inhibit natural killer-cell proliferation, cytotoxicity, and cytokine production: role of indoleamine 2,3-dioxygenase and prostaglandin E2. Blood (2007) 3.38
Interactions between human mesenchymal stem cells and natural killer cells. Stem Cells (2005) 3.36
Prospects for the use of NK cells in immunotherapy of human cancer. Nat Rev Immunol (2007) 3.33
Human bone marrow derived mesenchymal stem cells do not undergo transformation after long-term in vitro culture and do not exhibit telomere maintenance mechanisms. Cancer Res (2007) 3.19
Donor-derived mesenchymal stem cells are immunogenic in an allogeneic host and stimulate donor graft rejection in a nonmyeloablative setting. Blood (2006) 3.16
Immunomodulatory effect of human adipose tissue-derived adult stem cells: comparison with bone marrow mesenchymal stem cells. Br J Haematol (2005) 3.12
Interaction of human mesenchymal stem cells with cells involved in alloantigen-specific immune response favors the differentiation of CD4+ T-cell subsets expressing a regulatory/suppressive phenotype. Haematologica (2005) 3.11
Cell therapy using allogeneic bone marrow mesenchymal stem cells prevents tissue damage in collagen-induced arthritis. Arthritis Rheum (2007) 3.08
Adipose tissue-derived mesenchymal stem cells have in vivo immunosuppressive properties applicable for the control of the graft-versus-host disease. Stem Cells (2006) 3.02
Antitumor effect of genetically engineered mesenchymal stem cells in a rat glioma model. Gene Ther (2004) 2.97
Cotransplantation of HLA-identical sibling culture-expanded mesenchymal stem cells and hematopoietic stem cells in hematologic malignancy patients. Biol Blood Marrow Transplant (2005) 2.82
Cytokine expression by human marrow-derived mesenchymal progenitor cells in vitro: effects of dexamethasone and IL-1 alpha. J Cell Physiol (1996) 2.77
Mesenchymal stem cells effectively modulate pathogenic immune response in experimental autoimmune encephalomyelitis. Ann Neurol (2007) 2.64
Human mesenchymal stem cells xenografted directly to rat liver are differentiated into human hepatocytes without fusion. Blood (2005) 2.60
Mesenchymal stem cells inhibit the differentiation of dendritic cells through an interleukin-6-dependent mechanism. Stem Cells (2007) 2.54
Mesenchymal stem cells inhibit the formation of cytotoxic T lymphocytes, but not activated cytotoxic T lymphocytes or natural killer cells. Transplantation (2003) 2.49
Mesenchymal stem cells distribute to a wide range of tissues following systemic infusion into nonhuman primates. Blood (2002) 2.43
Allogeneic marrow stromal cells are immune rejected by MHC class I- and class II-mismatched recipient mice. Blood (2005) 2.39
Human mesenchymal stem cells support unrelated donor hematopoietic stem cells and suppress T-cell activation. Bone Marrow Transplant (2004) 2.36
Transplantation of mesenchymal stem cells to enhance engraftment of hematopoietic stem cells. Leukemia (2007) 2.35
Ex vivo expansion and subsequent infusion of human bone marrow-derived stromal progenitor cells (mesenchymal progenitor cells): implications for therapeutic use. Bone Marrow Transplant (1995) 2.35
Bone marrow mesenchymal progenitor cells inhibit lymphocyte proliferation by activation of the programmed death 1 pathway. Eur J Immunol (2005) 2.34
Effects of mesenchymal stem cells on differentiation, maturation, and function of human monocyte-derived dendritic cells. Stem Cells Dev (2004) 2.30
Generation of CD4+ or CD8+ regulatory T cells upon mesenchymal stem cell-lymphocyte interaction. Haematologica (2007) 2.30
Immunomodulatory effects of fetal and adult mesenchymal stem cells. Cytotherapy (2003) 2.28
Transplanted mesenchymal stem cells accelerate glomerular healing in experimental glomerulonephritis. J Am Soc Nephrol (2006) 2.24
Veto-like activity of mesenchymal stem cells: functional discrimination between cellular responses to alloantigens and recall antigens. J Immunol (2003) 2.21
Adult human fibroblasts are potent immunoregulatory cells and functionally equivalent to mesenchymal stem cells. J Immunol (2007) 2.19
Mesenchymal stem cells inhibit lymphocyte proliferation by mitogens and alloantigens by different mechanisms. Exp Cell Res (2005) 2.16
Bone marrow mesenchymal stem cells suppress lymphocyte proliferation in vitro but fail to prevent graft-versus-host disease in mice. J Immunol (2006) 2.16
Reversal of the immunosuppressive properties of mesenchymal stem cells by tumor necrosis factor alpha in collagen-induced arthritis. Arthritis Rheum (2005) 2.13
Toll-like receptors 3 and 4 are expressed by human bone marrow-derived mesenchymal stem cells and can inhibit their T-cell modulatory activity by impairing Notch signaling. Stem Cells (2007) 2.12
Human bone marrow stromal cell treatment improves neurological functional recovery in EAE mice. Exp Neurol (2005) 2.11
Xenotransplant cardiac chimera: immune tolerance of adult stem cells. Ann Thorac Surg (2002) 2.10
T cell responses to allogeneic human mesenchymal stem cells: immunogenicity, tolerance, and suppression. J Biomed Sci (2005) 2.07
Mesenchymal stem cells inhibit proliferation and apoptosis of tumor cells: impact on in vivo tumor growth. Leukemia (2006) 2.04
The role of mesenchymal stem cells in haemopoiesis. Blood Rev (2005) 1.98
Human mesenchymal stem cells inhibit neutrophil apoptosis: a model for neutrophil preservation in the bone marrow niche. Stem Cells (2007) 1.94
Human mesenchymal stem cells require monocyte-mediated activation to suppress alloreactive T cells. Exp Hematol (2005) 1.93
A role for heme oxygenase-1 in the immunosuppressive effect of adult rat and human mesenchymal stem cells. Blood (2007) 1.91
The antiproliferative effect of mesenchymal stem cells is a fundamental property shared by all stromal cells. J Immunol (2007) 1.89
Cellular ligands of activating NK receptors. Trends Immunol (2005) 1.84
Mesenchymal stem cells inhibit dendritic cell differentiation and function by preventing entry into the cell cycle. Transplantation (2007) 1.83
Antigen-presenting property of mesenchymal stem cells occurs during a narrow window at low levels of interferon-gamma. Blood (2006) 1.79
Mesenchymal stem cells are capable of homing to the bone marrow of non-human primates following systemic infusion. Exp Hematol (2001) 1.79
Reconstitution of the functional human hematopoietic microenvironment derived from human mesenchymal stem cells in the murine bone marrow compartment. Blood (2005) 1.76
Mesenchymal stem cells cooperate with bone marrow cells in therapy of diabetes. Stem Cells (2007) 1.73
Human marrow-derived mesenchymal stem cells (MSCs) express hematopoietic cytokines and support long-term hematopoiesis when differentiated toward stromal and osteogenic lineages. J Hematother Stem Cell Res (2000) 1.73
Mesenchymal stem cells inhibit the expression of CD25 (interleukin-2 receptor) and CD38 on phytohaemagglutinin-activated lymphocytes. Scand J Immunol (2004) 1.66
Homing of in vitro expanded Stro-1- or Stro-1+ human mesenchymal stem cells into the NOD/SCID mouse and their role in supporting human CD34 cell engraftment. Blood (2004) 1.65
Immunomodulatory effects of mesenchymal stem cells in a rat organ transplant model. Transplantation (2006) 1.64
Placenta-derived multipotent cells exhibit immunosuppressive properties that are enhanced in the presence of interferon-gamma. Stem Cells (2006) 1.63
HB-EGF/HER-1 signaling in bone marrow mesenchymal stem cells: inducing cell expansion and reversibly preventing multilineage differentiation. Blood (2005) 1.62
Interferon-gamma-stimulated marrow stromal cells: a new type of nonhematopoietic antigen-presenting cell. Blood (2005) 1.60
Human mesenchymal stem cells isolated from bone marrow and lymphoid organs support tumor B-cell growth: role of stromal cells in follicular lymphoma pathogenesis. Blood (2006) 1.58
Induction of neural-like differentiation in human mesenchymal stem cells derived from bone marrow, fat, spleen and thymus. Bone (2006) 1.49
Mesenchymal stem cells stimulate antibody secretion in human B cells. Scand J Immunol (2007) 1.46
Regulation of MHC class II expression and antigen processing in murine and human mesenchymal stromal cells by IFN-gamma, TGF-beta, and cell density. J Immunol (2007) 1.41
Failure of adult marrow-derived stem cells to generate marrow stroma after successful hematopoietic stem cell transplantation. Exp Hematol (2002) 1.39
Xenoreactivity and engraftment of human mesenchymal stem cells transplanted into infarcted rat myocardium. J Thorac Cardiovasc Surg (2004) 1.39
Cotransplantation of human mesenchymal stem cells enhances human myelopoiesis and megakaryocytopoiesis in NOD/SCID mice. Exp Hematol (2003) 1.35
HLA-G molecules: from maternal-fetal tolerance to tissue acceptance. Adv Immunol (2003) 1.33
The immunogenicity and immunomodulatory function of osteogenic cells differentiated from mesenchymal stem cells. J Immunol (2006) 1.32
Human mesenchymal stem cells promote survival of T cells in a quiescent state. Stem Cells (2007) 1.31
Engraftment of allogeneic mesenchymal stem cells in the bone marrow of a patient with severe idiopathic aplastic anemia improves stroma. Leukemia (2003) 1.29
Role for interferon-gamma in the immunomodulatory activity of human bone marrow mesenchymal stem cells. Stem Cells (2005) 4.26
Clinical treatment of radiotherapy tissue damage by lipoaspirate transplant: a healing process mediated by adipose-derived adult stem cells. Plast Reconstr Surg (2007) 4.00
Toll-like receptors 3 and 4 are expressed by human bone marrow-derived mesenchymal stem cells and can inhibit their T-cell modulatory activity by impairing Notch signaling. Stem Cells (2007) 2.12
Adipose-derived mesenchymal stem cells ameliorate chronic experimental autoimmune encephalomyelitis. Stem Cells (2009) 1.95
Human bone marrow and adipose tissue mesenchymal stem cells: a user's guide. Stem Cells Dev (2010) 1.78
HB-EGF/HER-1 signaling in bone marrow mesenchymal stem cells: inducing cell expansion and reversibly preventing multilineage differentiation. Blood (2005) 1.62
Efficacy of Helicobacter pylori eradication in raising platelet count in adult patients with idiopathic thrombocytopenic purpura. Haematologica (2002) 1.54
Induction of neural-like differentiation in human mesenchymal stem cells derived from bone marrow, fat, spleen and thymus. Bone (2006) 1.49
Bone marrow stromal cells and the upregulation of interleukin-8 production in human T-cell acute lymphoblastic leukemia through the CXCL12/CXCR4 axis and the NF-kappaB and JNK/AP-1 pathways. Haematologica (2008) 1.35
Regenerative and immunomodulatory potential of mesenchymal stem cells. Curr Opin Pharmacol (2006) 1.33
Clinical-grade mesenchymal stromal cells produced under various good manufacturing practice processes differ in their immunomodulatory properties: standardization of immune quality controls. Stem Cells Dev (2013) 1.26
Neuronal differentiation potential of human adipose-derived mesenchymal stem cells. Stem Cells Dev (2008) 1.24
Toll-like receptor-3-activated human mesenchymal stromal cells significantly prolong the survival and function of neutrophils. Stem Cells (2011) 1.22
Immune regulation by mesenchymal stem cells derived from adult spleen and thymus. Stem Cells Dev (2007) 1.19
Stem molecular signature of adipose-derived stromal cells. Exp Cell Res (2007) 1.17
Limited acquisition of chromosomal aberrations in human adult mesenchymal stromal cells. Cell Stem Cell (2012) 1.16
Macrophages may promote cancer growth via a GM-CSF/HB-EGF paracrine loop that is enhanced by CXCL12. Mol Cancer (2010) 1.16
Mesenchymal stem cells and autoimmune diseases. Best Pract Res Clin Haematol (2011) 1.16
Comparative study of immune regulatory properties of stem cells derived from different tissues. Stem Cells Dev (2013) 1.08
Notch-3 and Notch-4 signaling rescue from apoptosis human B-ALL cells in contact with human bone marrow-derived mesenchymal stromal cells. Blood (2011) 1.08
Nestin- and doublecortin-positive cells reside in adult spinal cord meninges and participate in injury-induced parenchymal reaction. Stem Cells (2011) 1.04
IFN-gamma-mediated upmodulation of MHC class I expression activates tumor-specific immune response in a mouse model of prostate cancer. Vaccine (2010) 1.02
Novel stem/progenitor cells with neuronal differentiation potential reside in the leptomeningeal niche. J Cell Mol Med (2009) 1.00
A multiplex reverse transcriptase-polymerase chain reaction strategy for the diagnostic molecular screening of chimeric genes: a clinical evaluation on 170 patients with acute lymphoblastic leukemia. Haematologica (2003) 1.00
Meninges: from protective membrane to stem cell niche. Am J Stem Cells (2012) 0.99
Methodological approach to minimal residual disease detection by flow cytometry in adult B-lineage acute lymphoblastic leukemia. Haematologica (2006) 0.98
MSCs: science and trials. Nat Med (2013) 0.97
A haplotype of the methylenetetrahydrofolate reductase gene predicts poor tumor response in rectal cancer patients receiving preoperative chemoradiation. Pharmacogenet Genomics (2006) 0.94
Neural stem cell niches in health and diseases. Curr Pharm Des (2012) 0.91
Comparison of epithelial differentiation and immune regulatory properties of mesenchymal stromal cells derived from human lung and bone marrow. PLoS One (2012) 0.89
The TNF-family cytokine TL1A inhibits proliferation of human activated B cells. PLoS One (2013) 0.89
Adipose-derived stromal cells (ASCs). Transfus Apher Sci (2012) 0.88
Immunological properties of embryonic and adult stem cells. World J Stem Cells (2010) 0.87
Interleukin 7 requirement for survival of T-cell acute lymphoblastic leukemia and human thymocytes on bone marrow stroma. Haematologica (2007) 0.87
Cell therapy for cardiac regeneration after myocardial infarct: which cell is the best? Cardiovasc Hematol Agents Med Chem (2010) 0.86
Induction of unresponsiveness limits tumor protection by adoptively transferred MDM2-specific cytotoxic T lymphocytes. Cancer Res (2004) 0.85
Immune regulatory properties of CD117(pos) amniotic fluid stem cells vary according to gestational age. Stem Cells Dev (2015) 0.85
DHFR 19-bp insertion/deletion polymorphism and MTHFR C677T in adult acute lymphoblastic leukaemia: is the risk reduction due to intracellular folate unbalancing? Am J Hematol (2009) 0.85
Thymic epithelial cells promote survival of human T-cell acute lymphoblastic leukemia blasts: the role of interleukin-7. Haematologica (2003) 0.84
Factors affecting successful mobilization with plerixafor: an Italian prospective survey in 215 patients with multiple myeloma and lymphoma. Transfusion (2013) 0.83
Normal hematopoiesis and hematologic malignancies: role of canonical Wnt signaling pathway and stromal microenvironment. Biochim Biophys Acta (2012) 0.82
Notch signaling in acute lymphoblastic leukemia: any role for stromal microenvironment? Blood (2011) 0.81
High prevalence of sustained remission of idiopathic thrombocytopenic purpura after Helicobacter pylori eradication: a long-term follow-up study. Platelets (2005) 0.80
Analysis of HFE and TFR2 gene mutations in patients with acute leukemia. Leuk Res (2005) 0.80
The puzzling uniqueness of the heterotrimeric G15 protein and its potential beyond hematopoiesis. J Mol Endocrinol (2010) 0.80
The impact of P53 and P21(waf1) expression on the survival of patients with the germinal center phenotype of diffuse large B-cell lymphoma. Haematologica (2006) 0.80
Deep vein thrombosis after orthopedic surgery in a patient with type 1 von Willebrand disease and mutations in the MTHFR and beta-fibrinogen genes. Thromb Haemost (2003) 0.80
Idiopathic thrombocytopenic purpura, Helicobacter pylori infection, and HLA class II alleles. Blood (2002) 0.79
Importance of epigenetic changes in cancer etiology, pathogenesis, clinical profiling, and treatment: what can be learned from hematologic malignancies? Biochim Biophys Acta (2013) 0.79
Effects of a ceramic biomaterial on immune modulatory properties and differentiation potential of human mesenchymal stromal cells of different origin. Tissue Eng Part A (2014) 0.78
Prevalence of hepatitis C virus infection in IgM-type monoclonal gammopathy of uncertain significance and Waldenström macroglobulinemia. Am J Hematol (2004) 0.78
Quantitative fluorescence in situ hybridization on paraffin embedded tissue. Methods Mol Biol (2013) 0.77
Plasmacytoid dendritic cell leukemia: a rapidly evolving disease presenting with skin lesions sensitive to radiotherapy plus hyperthermia. Oncologist (2009) 0.77
VR09 cell line: an EBV-positive lymphoblastoid cell line with in vivo characteristics of diffuse large B cell lymphoma of activated B-cell type. PLoS One (2012) 0.76
Efficacy assessment of interferon-alpha-engineered mesenchymal stromal cells in a mouse plasmacytoma model. Stem Cells Dev (2010) 0.76
Helicobacter pylori eradication in adults with idiopathic thrombocytopenic purpura. Am J Med (2003) 0.75
Iron overload in acute myeloid leukemia patients is not related to HFE and TFR2 gene mutations. Haematologica (2003) 0.75
Screening for hemochromatosis in a population with abnormal iron status. Haematologica (2003) 0.75
Low-dose epirubicin in combination with cyclophosphamide, vinblastine and prednisone (mini-CEOP) for the treatment of aggressive non-Hodgkin's lymphoma in elderly patients. Haematologica (2002) 0.75
Role of blood cells dynamism on hemostatic complications in low-risk patients with essential thrombocythemia. Intern Emerg Med (2015) 0.75
Quality of life in elderly patients with essential thrombocythaemia. An Italian multicentre study. Ann Hematol (2011) 0.75
Malignant evolution of monoclonal gammopathy of undetermined significance: analysis of 633 consecutive cases with a long term follow-up. Haematologica (2004) 0.75
Helicobacter pylori infection and idiopathic thrombocytopenic purpura: description of 21 newly diagnosed cases. Haematologica (2004) 0.75
In Vivo Effects of Mesenchymal Stromal Cells in Two Patients With Severe Acute Respiratory Distress Syndrome. Stem Cells Transl Med (2016) 0.75